SELTOUCH was launched in 1993 with Pfizer*1 and Takeda conducting distribution and marketing activities for the product. In July 2009, Pfizer*2 and ASKA signed an agreement related to the commercialization rights of the poultice formulation of SELTOUCH, while at the same time, ASKA and Takeda signed an agreement in which the distribution and marketing activities for that formulation of SELTOUCH were entrusted to Takeda. In 2011, a tape formulation was launched, and Pfizer entrusted the distribution and marketing activities for the tape formulation to Takeda. Presently, due to changes in the business environment surrounding all three companies, it has been decided in agreement with all three companies to conclude these agreements in order to maximize the product value of SELTOUCH.

The three companies will work closely to smoothly implement the marketing transfer of SELTOUCH. The companies remain committed to contributing to healthcare by providing therapeutical treatment options that address unmet needs of patients.

*1 Then Lederle Japan, Ltd.*2 Then Wyeth K.K.

# # #

Reference

About Wyeth Lederle Japan and Pfizer Japan Inc. history1998 Japan Lederle and Wyeth (Japan) Corporation were integrated together to form Wyeth Lederle Japan Ltd. (WLJ)2003 WLJ changed its name to Wyeth K. K. (WKK)2009 Wyeth was integrated into Pfizer2010 Japan-based Wyeth was integrated into Pfizer Japan Inc. to become the currently existing Pfizer Japan Inc.